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he Coronary Calcium Warranty
in et al. (1) provide welcome evidence that coronary artery
alcium (CAC) conversion from zero to a positive score occurs at
ow frequency before 4 years. They note that this finding applies to
middle-age, low- to intermediate-risk individuals,” in whom a
ero score is common. They are to be congratulated for the low
ose of radiation per scan (0.5 mSV).
Although readers are cautioned that repeat CAC testing has not
een formally recommended in any guideline to date, they may ask
ow to specifically apply these results to the population for whom
urrent guidelines endorse baseline CAC testing (2). The mean
ramingham risk score of the Min et al. (1) CAC  0 cohort was
%, placing many of the subjects in the low-risk group by National
holesterol Education Program guidelines (2). CAC scoring is not
urrently endorsed for patients at low risk (Framingham risk score
10%), as opposed to those at intermediate risk (Framingham risk
core, 10% to 20%), who may benefit from risk reclassification (2).
hus, the investigators’ recommended warranty period of 4 years
ay be too long when applied to classically intermediate-risk
atients undergoing CAC testing.
It would be beneficial for clinicians to have the “warranty
eriod” stratified by baseline risk group (10% and 10% to 20%).
t may even be prudent to stratify further, as some have advocated
or CAC testing in an expanded intermediate-risk group of 6% to
0% (e.g., 6%, 6% to 10%, and 10% to 20%) (3).
The finding that many traditional risk factors were not associ-
ted with the progression of CAC to a higher score in the baseline
AC 0 group is likely a function of the short duration of
ollow-up (1.9 years) and the definition of CAC progression in this
roup as “any increase in CAC score.” Progression results in this
roup may have been from interscan variability alone and not from
isease progression. Perhaps the investigators could have mini-
ized the effect of variability by incorporating a more specific and
linically meaningful cutoff (such as a 15% relative change
etween scans [4]).
The investigators may also have been overly prudent to suggest
hat “caution should be applied to interpreting our results among
atients who are not receiving lipid-lowering therapy.” Although
hey express concern that the 756 patients on statin therapy (72%)
ay have had retarded CAC progression, randomized trials to date
ave not shown that statin therapy can achieve this (5–6).
CAC  0 has enormous potential for ruling out important
oronary artery disease in asymptomatic patients. The duration and
pplication of the “warranty period” remains an important topic for
urther research.
John W. McEvoy, MB
ichael J. Blaha, MD, MPH
oger S. Blumenthal, MD rJohns Hopkins Hospital
iccarone Center for the Prevention of Heart Disease
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e thank Dr. McEvoy and colleagues for their interest in our
tudy (1). They raise several pertinent points that deserve response.
s noted, the mean 10-year coronary heart disease (CHD)
ramingham risk score for our study cohort with coronary artery
alcium (CAC) scores of zero was 9%, which comprised 62%
ow-risk (10% 10-year risk), 34% intermediate-risk (10% to 20%
0-year risk), and 5% high-risk (20% 10-year risk) patients.
lthough CAC scoring is not presently endorsed for low-risk
atients, we observed relationships of CAC conversion and time to
onversion in low-risk versus intermediate-risk patients that merit
onsideration.
Time to conversion to CAC 0 in low-risk patients did not
iffer compared with intermediate-risk patients (4.01 vs. 4.17
ears, p  0.99), and low-risk patients even trended toward higher
ates of conversion from CAC  0 to CAC 0 (11% vs. 8%, p 
.08). These findings are in keeping with recent population-based
tudies of CAC, including the Multiethnic Study of Atheroscle-
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September 14, 2010:995–9ramingham risk score across age, sex, and ethnic category, and
he Dallas Heart Study, in which CAC scores100 were observed
n a substantial proportion of low-risk patients who would not
therwise have been candidates for statin-based therapy (2,3).
iven the uneasiness on the part of many clinicians about relying
olely on the Framingham risk score (particularly in younger
omen and men and those with strong family histories of
remature CHD), the performance of CAC scoring in low-risk
atients may represent not only a clinical reality but also an
pportunity for improved stratification and reclassification of
HD risk.
Dr. McEvoy and colleagues also suggest that progression of
AC 0 to a higher CAC score may be due to the intermediate
ollow-up period of 1.9 years or interscan variability. Using the
clinically meaningful cutoff” of a 15% increase between CAC
cans they recommend, the relationship of increase in CAC
emains dependent solely on the baseline CAC score. In stepwise
ultivariate analyses, CAC 400 and CAC 600 were the only
redictive factors for CAC rise in both low-risk (hazard ratio: 2.08;
5% confidence interval: 1.29 to 3.35; p  0.003) and
ntermediate-risk (hazard ratio: 1.82; 95% confidence interval: 1.23
o 2.58; p  0.001) patients.
We agree with Dr. McEvoy and colleagues that many questions
elated to the potential effects of lipid-lowering therapies on CAC
emain unanswered, and we agree that CAC  0 holds great
otential for optimizing the classification of asymptomatic pa-
ients. We hope that our findings that demonstrate a 4-year
warranty period” of CAC  0 across all strata of CHD risk will
dd to the foundation of scientific evidence on which future studies
an be based, and in the interim, may inform physicians who use
AC scanning that retesting patients at intervals of 4 years is
nlikely to be helpful.
James K. Min, MD
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eslee J. Shaw, PhD
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Departments of Medicine and Radiology
eill Medical College of Cornell University
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ith interest we read the recent report by Sorajja et al. (1),
howing that delaying revascularization with percutaneous coro-
ary intervention (PCI) for 24 h in patients with acute coronary
yndrome was associated with an increased hazard for mortality
nd adverse ischemic outcomes, when compared with intervention
ithin 8 h or 8 to 24 h (1).
This finding was mainly driven by significantly more myocardial
nfarctions (MI) occurring in the delayed intervention group (24 h).
ecause of the natural course of cardiac biomarkers in the setting of
yocardial ischemia, procedure-related myonecrosis with immediate
ntervention is difficult to discern from elevated biomarker levels
efore PCI due to the index event. Thus, the diagnosis of procedure-
elated MI in early PCI is prone to detection bias.
Furthermore, the study had made a rather firm selection of
atients, because 4,491 patients who did not undergo PCI after
iagnostic angiography were left out. We hypothesize that patients
ith mild coronary artery disease underwent early PCI influenced by
he recent symptoms associated with the index event, whereas stabi-
ized patients with mild CAD undergoing delayed angiography did
ot undergo PCI and were excluded from the analysis. The authors
hould have at least reported outcomes by timing of angiography.
Finally, the Kaplan-Meier curves for mortality or MI continue
o diverge up to 30 days and thereafter. Apparently, the risk of
elaying intervention is not limited to an excess risk during the
aiting period, but also extends to the period after the interven-
ion. This observation is suggestive of patient selection for late PCI
ather than of an implicit higher risk of the intervention being
erformed at a later time point. This observation of selection bias
s corroborated by the observation that patients who received PCI
24 h had a worse baseline-risk profile and angiographic charac-
eristics. We note that the authors did not explain the higher death
r MI hazard with delayed intervention.
eter Damman, MD
an van Geloven, MSc
an G. P. Tijssen, PhD
Robbert J. de Winter, MD, PhD
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